Zu "K07370" wurden 160 Artikel gefunden!
Für die Filterung wurden keine Ergebnisse gefunden!
Remibrutinib
Artikelnummer: Cay44962-10
Remibrutinib is a covalent inhibitor of Bruton's tyrosine kinase (BTK. IC50 = 1. nM). It selectively binds to BTK over bone marrow tyrosine kinase on chromosome X (BMX) and Tec (Kds = 0. 540, and 110 nM, respectively), as well as IL-2-inducible T cell kinase (Itk), EGFR, HER2, HER4, and JAK3 (Kds = >10,000 nM for...
| Schlagworte: | LOU064,... |
| Anwendung: | BTK inhibitor |
| CAS | 1787294-07-8 |
| MW: | 507.54 D |
ab 93,00 €
Tolebrutinib
Artikelnummer: Cay37723-10
Tolebrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK, IC50 = 1 nM). It decreases the number of CD69+ B cells in isolated mouse whole blood (IC50 = 200 nM).Formal Name: 4-amino-1,3-dihydro-1-[(3R)-1-(1-oxo-2-propen-1-yl)-3-piperidinyl]-3-(4-phenoxyphenyl)-2H-imidazo[4,5-c]pyridin-2-one. CAS...
| Schlagworte: | 4-amino-1,3-dihydro-1-[(3R)-1-(1-oxo-2-propen-1-yl)-3-piperidinyl]-3-(4-phenoxyphenyl)-2H-imidazo[4,5-c]pyridin-2-one |
| Anwendung: | Irreversible BTK inhibitor |
| CAS | 1971920-73-6 |
| MW: | 455.5 D |
ab 103,00 €
Ibrutinib
Artikelnummer: Cay16274-1
Bruton's tyrosine kinase (BTK) is a member of the BTK/Tec family of protein tyrosine kinases involved in signal transduction pathways regulating proliferation, survival, migration, and tissue homing of B-cells. Ibrutinib is an irreversible inhibitor of BTK (IC50 = 0.5 nM) that selectively blocks B cell activation,...
| Schlagworte: | Imbruvica, PCI 32765, 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one |
| Anwendung: | BTK inhibitor |
| CAS | 936563-96-1 |
| MW: | 440.5 D |
ab 56,00 €
NX-5948
Artikelnummer: Cay43484-1
NX-5948 is a proteolysis-targeting chimera (PROTAC) that drives the degradation of Bruton's tyrosine kinase (BTK). SMILES NC(C1=C(N=C(N2C[C@H](N3C(N(CC3)C)=O)CCC2)C=N1)NC4=CC=C(C5CCN(CC5)CC6CCN(C7=CN=C(C=C7)C(N[C@H]8CCC(NC8=O)=O)=O)CC6)C=C4)=O InChi Code...
| Schlagworte: | 3-[[4-[1-[[1-[6-[[[(3S)-2,6-dioxo-3-piperidinyl]amino]carbonyl]-3-pyridinyl]-4-piperidinyl]methyl]-4-piperidinyl]phenyl]am... |
| Anwendung: | BTK degradation driving PROTAC |
| CAS | 2649400-34-8 |
| MW: | 806.97 D |
ab 60,00 €
BIIB129
Artikelnummer: Cay43712-10
BIIB129 is a covalent inhibitor of Bruton's tyrosine kinase (BTK). It is selective for BTK over a panel of 403 additional kinases at 1 µM. BIIB129 inhibits CD69 activation in isolated human whole blood (IC50 = 7.9 nM). In vivo, BIIB129 inhibits anti-myelin oligodendrocyte glycoprotein (MOG) antibody-induced...
| Schlagworte: | N-methyl-N-[cis-3-methyl-3-[[6-(1-methyl-1Hpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxy]cyclobutyl]-2-propenamide |
| Anwendung: | Covalent BTK inhibitor |
| CAS | 2770960-52-4 |
| MW: | 366.43 D |
ab 123,00 €
PRN-1008
Artikelnummer: Cay42239-10
A BTK inhibitor. Formulation: A solid. InChI: InChI=1S/C36H40FN9O3/c1-36(2,45-15-13-43(14-16-45)26-21-48-22-26)18-24(19-38)35(47)44-12-6-7-25(20-44)46-34-31(33(39)40-23-41-34)32(42-46)29-11-10-28(17-30(29)37)49-27-8-4-3-5-9-27/h3-5,8-11,17-18,23,25-26H,6-7,12-16,20-22H2,1-2H3,(H2,39,40,41)/b24-18+/t25-/m1/s1....
| Schlagworte: | Rilzabrutinib,... |
| Anwendung: | BTK inhibitor |
| CAS | 1575596-29-0 |
| MW: | 665.8 D |
ab 409,00 €
Ibrutinib
Artikelnummer: AG-CR1-3620-M005
White solid. Soluble in DMSO. Slightly soluble in ethanol (1mg/ml). Insoluble in water. Potent and highly selective Bruton's tyrosine kinase (BTK) inhibitor. Orally bioavailable and irreversible inhibitor of BTK (IC50 = 0.5 nM) with antineoplastic activity, Binds to and irreversibly inhibits BTK activity, preventing...
| Schlagworte: | PCI-32765 |
| Anwendung: | BTK inhibitor |
| CAS | 936563-96-1 |
| MW: | 440,5 D |
ab 88,00 €
Anti-BTK
Artikelnummer: NSJ-F52632-0.08ML
In 1X PBS, pH 7.4, with 0.09% sodium azide. Non-receptor tyrosine kinase indispensable for B lymphocyte development, differentiation and signaling. Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation. After BCR engagement and activation at the plasma...
| Schlagworte: | Anti-BPK, Anti-ATK, Anti-BTK, Anti-AGMX1, EC=2.7.10.2, Anti-Bruton tyrosine kinase, Anti-B-cell progenitor kinase,... |
| Anwendung: | WB, ELISA |
| Wirt: | Rabbit |
| Spezies-Reaktivität: | human, mouse |
ab 361,00 €
PCI-32765
Artikelnummer: LKT-P0932.1
PCI-32765 is an irreversible inhibitor of Bruton's tyrosine kinase (BTK), an enzyme that plays a significant role in B-cell receptor signaling and B-cell malignancies and autoimmune diseases such as x-linked agammaglobulinemia, chronic lymphocytic leukemia, and non-Hodgkin's lymphoma. PCI-32765's inhibition of BTK...
| Schlagworte: | Ibrutinib |
| Anwendung: | Bruton's tyrosine kinase inhibitor |
| CAS | 936563-96-1 |
| MW: | 440.5 D |
ab 104,00 €
Acalabrutinib
Artikelnummer: Cay19899-5
Acalabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (BTK). It can dose-dependently inhibit B cell receptor signaling in primary chronic lymphocytic leukemia cells. In kinase-inhibition assays, acalabrutinib was more selective than ibrutinib (Cay-16274) for inhibiting BTK and did not inhibit EGFR,...
| Schlagworte: | ACP-196, 4-[8-amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinyl-benzamide |
| Anwendung: | BTK inhibitor |
| CAS | 1420477-60-6 |
| MW: | 465.5 D |
ab 49,00 €
CGI1746
Artikelnummer: Cay18414-5
CGI1746 is a potent, selective inhibitor of Bruton's tyrosine kinase (BTK, IC50 = 1.9 nM), a non-receptor tyrosine kinase that is important in B lymphocyte development. It blocks both auto-and trans-phosphorylation of BTK by occupying an SH3 binding pocket in the un-phosphorylated enzyme. CGI1746 prevents B-cell...
| Schlagworte: | N-[3-[4,5-dihydro-4-methyl-6-[[4-(4-morpholinylcarbonyl)phenyl]amino]-5-oxo-2-pyrazinyl]-2-methylphenyl]-4-(1,1-dimethylet... |
| Anwendung: | Btk inhibitor |
| CAS | 910232-84-7 |
| MW: | 579.7 D |
ab 44,00 €
AVL-292
Artikelnummer: LKT-A8644.25
AVL-292 is a Bruton's tyrosine kinase (BTK) inhibitor that exhibits anticancer chemotherapeutic activities. AVL-292 is in clinical development as a potential treatment for B-cell-related disorders such as chronic lymphocytic leukemia (CLL).
| Schlagworte: | CC-292 |
| Anwendung: | BTK inhibitor |
| CAS | 1202757-89-8 |
| MW: | 423.44 D |
ab 94,00 €